Polymer Capital Management HK LTD Makes New $944,000 Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Polymer Capital Management HK LTD acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,098 shares of the company’s stock, valued at approximately $944,000.

A number of other institutional investors also recently modified their holdings of NRIX. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares during the last quarter. Quarry LP increased its stake in shares of Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after buying an additional 2,435 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $209,000. EP Wealth Advisors LLC purchased a new stake in Nurix Therapeutics in the third quarter worth $240,000. Finally, EntryPoint Capital LLC bought a new stake in Nurix Therapeutics in the fourth quarter valued at $266,000.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $9.69 on Monday. The firm has a market cap of $738.73 million, a P/E ratio of -3.35 and a beta of 2.23. Nurix Therapeutics, Inc. has a fifty-two week low of $9.45 and a fifty-two week high of $29.56. The firm has a 50-day simple moving average of $15.45 and a two-hundred day simple moving average of $19.86.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,326 shares of company stock valued at $213,449. Corporate insiders own 7.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Stifel Nicolaus raised their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. BTIG Research assumed coverage on Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 target price on the stock. Leerink Partners started coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a “market perform” rating and a $16.00 target price for the company. Finally, Royal Bank of Canada upped their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.88.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.